Journal
EMBO MOLECULAR MEDICINE
Volume 8, Issue 1, Pages 6-24Publisher
WILEY
DOI: 10.15252/emmm.201505433
Keywords
CCM; EndMT; endothelial cells; KLF4; TGF beta-BMP
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro [14471]
- Special Program Molecular Clinical Oncology 5x1000
- European Research Council (project EU-ERC) [268870]
- European Community [ITN VESSEL 317250, ENDOSTEM-HEALTH-2009-241440]
- Telethon [GGP14149]
- Brains barriers training (BtRAIN) [675619]
- Cariplo Foundation [2014-1038]
- AIRC fellowship [16617]
- European Research Council (ERC) [268870] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Cerebral cavernous malformations (CCMs) are vascular malformations located within the central nervous system often resulting in cerebral hemorrhage. Pharmacological treatment is needed, since current therapy is limited to neurosurgery. Familial CCM is caused by loss-of-function mutations in any of Ccm1, Ccm2, and Ccm3 genes. CCM cavernomas are lined by endothelial cells (ECs) undergoing endothelial-to-mesenchymal transition (EndMT). This switch in phenotype is due to the activation of the transforming growth factor beta/bone morphogenetic protein (TGFb/BMP) signaling. However, the mechanism linking Ccm gene inactivation and TGFb/ BMP-dependent EndMT remains undefined. Here, we report that Ccm1 ablation leads to the activation of a MEKK3-MEK5-ERK5MEF2 signaling axis that induces a strong increase in Kruppel-like factor 4 (KLF4) in ECs in vivo. KLF4 transcriptional activity is responsible for the EndMT occurring in CCM1-null ECs. KLF4 promotes TGFb/BMP signaling through the production of BMP6. Importantly, in endothelial-specific Ccm1 and Klf4 double knockout mice, we observe a strong reduction in the development of CCM and mouse mortality. Our data unveil KLF4 as a therapeutic target for CCM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available